WCG acquires PharmaSeek, to offer ‘unprecedented’ site support and guidance

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/AndreyPopov)
(Image: Getty/AndreyPopov)

Related tags: WCG, PharmaSeek, Clinical trial sites

Through the combined offerings of WCG and PharmaSeek, the companies will be able to make a clinical trial site’s success both ‘predictable and achievable,’ says CEO.

WIRB-Copernicus Group’s (WCG) Clinical Services Division as acquired PharmaSeek and its wholly-owned subsidiaries PFS Clinical and PatientWise, which provide administrative, consulting, patient recruitment, and training solutions for clinical research sites.

Nicolas Cindric, PharmaSeek CEO, told us the company has been approached for acquisition in the past, but never found the right fit. “With WCG, the stars just seemed to align,”​ he said.

PharmaSeek will continue to operate independently from its headquarters in Madison, WI, with access to capital, expertise, and corporate operational support from WCG. PharmaSeek clients also will be invited to join WCG’s Global Research Network (GRN).

“The clinical research landscape is changing,”​ said Donald Deieso, PhD, executive chairman and CEO, WCG, “protocols are more complex and research sponsors are using fewer sites.”

“In order to increase profitability, sites must maximize the efficiency with which they conduct existing research while positioning themselves to attract additional sponsor funding. A challenging proposition to even the most experienced sites, this ‘two-step’ is particularly difficult for newcomers, and is often perceived as a barrier to entry,”​ Deieso told us.

To encourage first-time investigators and new sites to participate in clinical research, Deieso said it is ‘imperative’ that the industry provide accessible solutions that enable sites to benchmark performance, manage study-related activities, increase patient enrollment, and simplify payments.

Said Deieso, “Through the power of our combined solutions, WCG and PharmaSeek offer unprecedented support and guidance, making a site’s success both predictable and achievable.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more